Clinical Trial Update: FeNO as a Marker of Allergic Reactions to OFC and Response of OMA Treatment in Multiple FA [Phase 4]

View source ↗

Summary

Phase 4 clinical trial update evaluating whether FeNO can serve as a biomarker for allergic reactions during oral food challenges and the effectiveness of omali…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Food Allergy

Drugs mentioned

• Omalizumab (Omalizumab)

Snippet

Sponsor: AAADRS Clinical Research Center | Conditions: Food Allergy | Phase 4 | Status: ACTIVE_NOT_RECRUITING